Status:

COMPLETED

Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation

Lead Sponsor:

CardioFocus

Conditions:

Paroxysmal Atrial Fibrillation

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This is a demonstration of safety and efficacy of the ablation for pulmonary vein isolation in the treatment of paroxysmal atrial fibrillation.

Eligibility Criteria

Inclusion

  • 18 to 70 years
  • paroxysmal atrial fibrillation
  • failure of at least one AAD
  • others

Exclusion

  • overall good health as established by multiple criteria

Key Trial Info

Start Date :

September 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2012

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00971204

Start Date

September 1 2009

End Date

June 1 2012

Last Update

August 1 2016

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35294

2

Pacific Heart Institute

Santa Monica, California, United States, 90404

3

William Beaumont Hospital

Royal Oak, Michigan, United States, 48072

4

Mt. Sinai Hospital

New York, New York, United States, 10029

Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation | DecenTrialz